Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
#2954 Aggressive Resection - A Treatment Option in Patients with Advanced Neuroendocrine Tumors
Introduction: Different treatment modalities have been considered for patients with malignant advanced neuroendocrine tumors(NETs) of the pancreas and duodenum.Aggressive surgery remains a controversial yet an efficacious antitumor therapy.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Athar A,
Keywords: Surgical resection, Advanced NET,
Introduction: The identification of a sensitive biomarker to detect the presence and severity of carcinoid heart disease could allow more selective use of clinical and echocardiographic screening. ST2 is a protein belonging to the family of interleukin 1 receptors, present both in the isoform of transmembrane (ST2L) and in the soluble one (sST2). sST2 blocks the anti-inflammatory, anti-hypertrophic, and anti-fibrotic effects of cytokine IL-33 on the myocardium and recent studies have shown that sST2 levels increase in the blood of patients diagnosed with heart failure.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Salvatici M, Zorzino L, Fabiani I, Cardinale D, Fazio N,
Keywords: sST2, Biomarkers, Carcinoid Heart Disease,
Introduction: 177Lu-DOTATATE is an effective therapy for somatostatin receptor-positive neuroendocrine tumors (NETs). Often enough 177Lu-DOTATATE is used as the last treatment resort in advanced NET.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Song H, Kunz P, Franc B, Moradi F, Fisher G,
Keywords: 177Lu-DOTATATE, PRRT, 68Ga-DOTATATE PET, Chromogranin A, 68Ga-DOTATATE avid tumor volume,
Introduction: While 5HT is considered the main causative agent for carcinoid heart disease (CHD, not all pts with elevated 24h-urinary 5HIAA (u5HIAA) develop CHD.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Riechelmann R
Authors: Riechelmann R, Mesquita M, Alves C, Silva C, Soeiro M,
Keywords: carcinoid heart disease, neuroendocrine, prognostic, carcinoid syndrome,
Introduction: In advanced NETs antiproliferative treatment options beyond somatostatin analogues remain limited. Temozolomide (TMZ) has shown efficacy in NETs alone or combined with other drugs.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Pavel M, Denecke T, Lahner H, Hörsch D, Rinke A,
Keywords: lanreotide, temozolomide, somatostatin analogues, combination therapy, progressive advanced NET, SONNET,